Reimbursement Questions Add To Compounding Regulation Debate
Public Citizen asks whether CMS policy could have helped prevent the drug contamination at New England Compounding Center as Senate committee wants more information on states’ regulatory practices.
You may also be interested in...
CMS Doubts Power Of Purse To Stem Public Health Crises With Compounded Drugs
Medicare agency disagrees with HHS Office of Inspector General recommendation that providers be required to identify the source of compounded drugs submitted for Part B payment.
FDA Compounder Inspections: States Taking Early Leave
State inspectors did not accompany FDA for the full duration of facility inspections and now the agency is turning over the findings to them.
HHS Inspector General Investigating Drug Savings For Medicare In FY 2014 Work Plan
OIG is examining how Medicare could benefit if it shared in the drug discounts available through the 340B program, the potential impact of changes to Part B ASP reporting and other Medicare and Medicaid drug-related topics during this and the coming fiscal year.